DAWN SMEDLEY: Open Payments
NPI 1104361864 · FAYETTEVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$493 in 28 payments from 11 companies in 2025. Trend: 2023 $459 · 2024 $302 · 2025 $493
Food & beverage: $493
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $195 |
| Amgen Inc. | 5 | $93 |
| E.R. Squibb & Sons, L.L.C. | 3 | $58 |
| Novo Nordisk Inc | 1 | $25 |
| Abbott Laboratories | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| CVRx, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| Novartis Pharmaceuticals Corporation | 1 | $15 |
Products named: VYNDAQEL, REPATHA, ELIQUIS, Wegovy, CARDIOMEMS, CAMZYOS, UPTRAVI, Barostim Neo System.
Industry payments across AR — which companies pay providers there.
